These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 36152702)

  • 1. A SARS-CoV-2 vaccine based on conjugation of SARS-CoV-2 RBD with IC28 peptide and mannan.
    He Y; Yu W; Shen L; Yan W; Xiao L; Qi J; Hu T
    Int J Biol Macromol; 2022 Dec; 222(Pt A):661-670. PubMed ID: 36152702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A SARS-CoV-2 nanoparticle vaccine based on chemical conjugation of loxoribine and SpyCatcher/SpyTag.
    Yan W; Yu W; Shen L; Xiao L; Qi J; Hu T
    Int J Biol Macromol; 2023 Dec; 253(Pt 5):127159. PubMed ID: 37778577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant COVID-19 vaccine based on recombinant RBD/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity.
    Ghaemi A; Roshani Asl P; Zargaran H; Ahmadi D; Hashimi AA; Abdolalipour E; Bathaeian S; Miri SM
    Front Immunol; 2022; 13():974364. PubMed ID: 36159845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the immunogenicity of gold nanoparticles conjugated RBD with Freund's adjuvant as a potential vaccine against SARS-CoV-2.
    Moshref Javadi M; Taghdisi Hosseinzadeh M; Soleimani N; Rommasi F
    Microb Pathog; 2022 Sep; 170():105687. PubMed ID: 35917987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine.
    Li CJ; Jiang CL; Chao TL; Lin SY; Tsai YM; Chao CS; Su YT; Chen CJ; Chang SY; Lin FJ; Chang SC
    Appl Microbiol Biotechnol; 2023 May; 107(9):2983-2995. PubMed ID: 36988669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.
    Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X
    Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus.
    Brzuska G; Zimna M; Baranska K; Szewczyk B; Strakova P; Ruzek D; Krol E
    Microbiol Spectr; 2023 Jun; 11(3):e0256422. PubMed ID: 37199661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical study of a DNA vaccine targeting SARS-CoV-2.
    Hayashi H; Sun J; Yanagida Y; Otera T; Kubota-Koketsu R; Shioda T; Ono C; Matsuura Y; Arase H; Yoshida S; Nakamaru R; Ju N; Ide R; Tenma A; Kawabata S; Ehara T; Sakaguchi M; Tomioka H; Shimamura M; Okamoto S; Amaishi Y; Chono H; Mineno J; Komatsuno T; Saito Y; Rakugi H; Morishita R; Nakagami H
    Curr Res Transl Med; 2022 Sep; 70(4):103348. PubMed ID: 35489099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An
    Brindha S; Yoshizue T; Wongnak R; Takemae H; Oba M; Mizutani T; Kuroda Y
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of a silica nanoparticle-based SARS-CoV-2 vaccine in mice.
    Barbey C; Su J; Billmeier M; Stefan N; Bester R; Carnell G; Temperton N; Heeney J; Protzer U; Breunig M; Wagner R; Peterhoff D
    Eur J Pharm Biopharm; 2023 Nov; 192():41-55. PubMed ID: 37774890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral Immune Response Diversity to Different COVID-19 Vaccines: Implications for the "Green Pass" Policy.
    Polvere I; Parrella A; Zerillo L; Voccola S; Cardinale G; D'Andrea S; Madera JR; Stilo R; Vito P; Zotti T
    Front Immunol; 2022; 13():833085. PubMed ID: 35634315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucosal SARS-CoV-2 Nanoparticle Vaccine Based on Mucosal Adjuvants and Its Immune Effectiveness by Intranasal Administration.
    Xiao L; Yu W; Shen L; Yan W; Qi J; Hu T
    ACS Appl Mater Interfaces; 2023 Aug; 15(30):35895-35905. PubMed ID: 37466148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor-binding domain-based SARS-CoV-2 vaccine adjuvanted with cyclic di-adenosine monophosphate enhances humoral and cellular immunity in mice.
    Germanó MJ; Giai C; Cargnelutti DE; Colombo MI; Blanco S; Konigheim B; Spinsanti L; Aguilar J; Gallego S; Valdez HA; Mackern-Oberti JP; Sanchez MV
    J Med Virol; 2023 Feb; 95(2):e28584. PubMed ID: 36794675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2.
    Wang S; Wang CY; Kuo HK; Peng WJ; Huang JH; Kuo BS; Lin F; Liu YJ; Liu Z; Wu HT; Ding S; Hou KL; Cheng J; Yang YT; Jiang MH; Wang MS; Chen T; Xia WG; Lin E; Hung CH; Chen HJ; Shih Z; Lin YL; Ryan V; Hu MM; Heppner DG; Malherbe DC; Periasamy S; Kuzmina N; Subramani C; Hellerstein M; Monath TP; Rumyantsev A; Bukreyev A; Guirakhoo F
    Emerg Microbes Infect; 2022 Dec; 11(1):2724-2734. PubMed ID: 36287714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.
    Liu Z; Xu W; Xia S; Gu C; Wang X; Wang Q; Zhou J; Wu Y; Cai X; Qu D; Ying T; Xie Y; Lu L; Yuan Z; Jiang S
    Signal Transduct Target Ther; 2020 Nov; 5(1):282. PubMed ID: 33247109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation.
    Jeong H; Choi YM; Seo H; Kim BJ
    Front Immunol; 2021; 12():637654. PubMed ID: 33732258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.